Development of a real-time polymerase chain reaction-based method for the measurement of relative allelic expression and identification of CYP2A13 alleles with decreased expression in human lung

Journal of Pharmacology and Experimental Therapeutics

Volumn 311, Issue 1, 2004, Pages 373-381

  Zhang, Xiuling ^a   Caggana, Michele ^a   Cutler, Tracey L ^a   Ding, Xinxin ^a,b  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b WADSWORTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2A; CYTOCHROME P450 2A13; DNA; MESSENGER RNA; NITROSAMINE; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADULT; AFRICAN AMERICAN; AGED; ALLELISM; ARTICLE; ASIAN; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CAUCASIAN; FEMALE; GENE EXPRESSION; HAPLOTYPE; HETEROZYGOSITY; HISPANIC; HUMAN; HUMAN TISSUE; LUNG; LUNG TUMOR; MALE; NEWBORN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TOBACCO; UNITED STATES;

ADULT; ALLELES; ARYL HYDROCARBON HYDROXYLASES; ETHNIC GROUPS; GENE EXPRESSION; GENE FREQUENCY; HETEROZYGOTE; HUMANS; LUNG; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 4644227631     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.069872     Document Type: Article

References (37)

1. Aklillu E, Carrillo JA, Makonnen E, Hellman K, Pitarque M, Bertilsson L, and Ingelman-Sundberg M (2003) Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol 64:659-669.
2. Allorge D, Chevalier D, Lo-Guidice JM, Cauffiez C, Suard F, Baumann P, Eap CB, and Broly F (2003) Identification of a novel splice-site mutation in the CYP1A2 gene. Br J Clin Pharmacol 56:341-344.
3. Bray NJ, Buckland PR, Williams NM, Williams HJ, Norton N, Owen MJ, and O'Donovan MC (2003) A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain. Am J Hum Genet 73:152-161.
4. Caggana M, Conroy JM, and Pass KA (1998) Rapid, efficient method for multiplex amplification from filter paper. Hum Mutat 11:404-409.
5. Cauffiez C, Lo-Guidice JM, Quaranta S, Allorge D, Chevalier D, Cenee S, Hamdan R, Lhermitte M, Lafitte JJ, Libersa C, et al. (2004) Genetic polymorphism of the human cytochrome CYP2A13 in a French population: implication in lung cancer susceptibility. Biochem Biophys Res Commun 317:662-669.
6. Chen Y, Liu YQ, Su T, Ren X, Shi L, Liu DZ, Gu J, Zhang Q-Y, and Ding X (2003) Immunoblot analysis and immunohistochemical characterization of CYP2A expression in human olfactory mucosa. Biochem Pharmacol 66:1245-1251.
7. Cheng XY, Chen GL, Zhang WX, Zhou G, Wang D, and Zhou HH (2004) Arg257Cys polymorphism of CYP2A13 in a Chinese population. Clin Chim Acta 343:213-216.
8. Cowles CR, Hirschhorn JN, Altshuler D, and Lander ES (2002) Detection of regulatory variation in mouse genes. Nat Genet 32:432-437.
9. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, and Goldstein JA (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419-15422.
10. Di Paola R, Frittitta L, Miscio G, Bozzali M, Baratta R, Centra M, Spampinato D, Santagati MG, Ercolino T, Cisternino C, et al. (2002) A variation in 3′ UTR of hPTP1B increases specific gene expression and associates with insulin resistance. Am J Hum Genet 70:806-812.
11. Fernandez-Salguero P, Hoffman SM, Cholerton S, Mohrenweiser H, Raunio H, Rautio A, Pelkonen O, Huang JD, Evans WE, and Idle JR (1995) A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Genet 57:651-660.
12. Frittitta L, Ercolino T, Bozzali M, Argiolas A, Graci S, Santagati MG, Spampinato D, Di Paola R, Cisternino C, Tassi V, et al. (2001) A cluster of three single nucleotide polymorphisms in the 3′-untranslated region of human glycoprotein PC-1 gene stabilizes PC-1 mRNA and is associated with increased PC-1 protein content and insulin resistance-related abnormalities. Diabetes 50:1952-1955.
13. Fujieda M, Yamazaki H, Kiyotani K, Muroi A, Kunitoh H, Dosaka-Akita H, Sawamura Y, and Kamataki T (2003) Eighteen novel polymorphisms of the CYP2A13 gene in Japanese. Drug Metab Pharmacokinet 18:86-90.
14. Gu J, Su T, Chen Y, Zhang Q-Y, and Ding X (2000) Expression of biotransformation enzymes in human fetal olfactory mucosa: potential roles in developmental toxicity. Toxicol Appl Pharmacol 165:158-162.
15. Hoffman SM, Nelson DR, and Keeney DS (2001) Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19. Pharmacogenetics 11:687-698.
16. Hurteau GJ and Spivack SD (2002) mRNA-specific reverse transcription-polymerase chain reaction from human tissue extracts. Anal Biochem 307:304-315.
17. Ibeanu GC, Blaisdell J, Ferguson RJ, Ghanayem BI, Brosen K, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, and Goldstein JA (1999) A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther 290:635-640.
18. Jalas JR, Ding X, and Murphy SE (2003) Comparative metabolism of the tobacco-specific nitrosamines 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol by rat cytochrome P450 2A3 and human cytochrome P450 2A13. Drug Metab Dispos 31:1199-1202.
19. Kiyotani K, Yamazaki H, Fujieda M, Iwano S, Matsumura K, Satarug S, Ujjin P, Shimada T, Guengerich FP, Parkinson A, et al. (2003) Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9). Pharmacogenetics 13: 689-695.
20. Koskela S, Hakkola J, Hukkanen J, Pelkonen O, Sorri M, Saranen A, Anttila S, Fernandez-Salguero P, Gonzalez F, and Raunio H (1999) Expression of CYP2A genes in human liver and extrahepatic tissues. Biochem Pharmacol 57:1407-1413.
21. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391.
22. Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock ML, Fackenthal JD, Rogan PK, Ring B, Wrighton SA, et al. (2003) Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 307:906-922.
23. Lossos IS, Czerwinski DK, Wechser MA, and Levy R (2003) Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies. Leukemia 17:789-795.
24. Matyas G, Giunta C, Steinmann B, Hossle JP, and Hellwig R (2002) Quantification of single nucleotide polymorphisms: a novel method that combines primer extension assay and capillary electrophoresis. Hum Mutat 19:58-68.
25. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, and Kamataki T (1999) Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem 125:803-808.
26. Newcombe RG (1998) Two-sided confidence intervals for the single proportion - comparison of seven methods. Stat Med 17:857-872.
27. Pitarque M, von Richter O, Oke B, Berkkan H, Oscarson M, and Ingelman-Sundberg M (2001) Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem Biophys Res Commun 284:455-460.
28. Pitarque M, von Richter O, Rodriguez-Antona C, Wang J, Oscarson M, and Ingelman-Sundberg M (2004) A nicotine C-oxidase gene (CYP2A6) polymorphism important for promoter activity. Hum Mutat 23:258-266.
29. Sachse C, Brockmoller J, Bauer S, and Roots I (1999) Functional significance of a C-> A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47:445-449.
30. Saito S, Iida A, Sekine A, Kawauchi S, Higuchi S, Ogawa C, and Nakamura Y (2003) Catalog of 178 variations in the Japanese population among eight human genes encoding G protein-coupled receptors (GPCRs). J Hum Genet 48:461-468.
31. Sheng JJ, Guo JC, Hua ZC, Caggana M, and Ding X (2000) Characterization of human CYP2G genes: widespread loss-of-function mutations and genetic polymorphism. Pharmacogenetics 10:667-678.
32. Su T, Bao Z, Zhang Q-Y, Smith TJ, Hong J-Y, and Ding X (2000) Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res 60:5074-5079.
33. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, and Speleman F (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3:1-12.
34. Wang HJ, Tan W, Hao BT, Miao XP, Zhou GQ, He FH, and Lin DX (2003) Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. Cancer Res 63:8057-8061.
35. Yan H, Yuan W, Velculescu VE, Vogelstein B, and Kinzler KW (2002) Allelic variation in human gene expression. Science (Wash DC) 297:1143.
36. Zhang XL, Chen Y, Liu YQ, Ren X, Zhang Q-Y, Caggana M, and Ding X (2003) Single nucleotide polymorphisms of the human CYP2A13 gene: evidence for a null allele. Drug Metab Dispos 31:1081-1085.
37. Zhang XL, Su T, Zhang Q-Y, Gu J, Caggana M, Li H, and Ding X (2002) Genetic polymorphisms of the human CYP2A13 gene: identification of single-nucleotide polymorphisms and functional characterization of an Arg257Cys variant. J Pharmacol Exp Ther 302:416-423.